Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor. PF-06459988 has high efficiency and high affinity for EGFRs double mutants containing T790M, and has minimal activity against WT EGFR. PF-06459988 makes a candidate drug for the treatment of cancer.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 82.00 |
Description | PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor. PF-06459988 has high efficiency and high affinity for EGFRs double mutants containing T790M, and has minimal activity against WT EGFR. PF-06459988 makes a candidate drug for the treatment of cancer. |
Targets&IC50 | EGFR:3.3 μM, H1975 EGFR:45 nM |
Molecular Weight | 431.88 |
Formula | C19H22ClN7O3 |
CAS No. | 1428774-45-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (104.19 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-06459988 1428774-45-1 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR irreversible oral T790M Inhibitor HER1 PF06459988 NSCLC inhibit Epidermal growth factor receptor cancer PF 06459988 ErbB-1 inhibitor